GERMANTOWN, Md., Nov. 4, 2019 /PRNewswire/ -- Intrexon
Corporation (NASDAQ: XON), a leader in the engineering and
industrialization of biology to improve the quality of life and
health of the planet, today announced it will release third quarter
financial results before the market opens on Tuesday, November 12th, 2019.
Precigen, Inc., a biopharmaceutical company specializing in the
development of innovative gene and cellular therapies to improve
the lives of patients and a wholly owned subsidiary of Intrexon,
will host a conference call that day at 11:00 AM ET to provide Precigen business and
pipeline updates.
The conference call may be accessed by dialing 1-888-317-6003
(Domestic US), 1-866-284-3684 (Canada), and
1‑412-317-6061 (International) and providing the number
4454504 to join the Precigen Business and Pipeline Update
Call. Participants may also access the live webcast through
Intrexon's website in the Investors section at
http://investors.dna.com/events or Precigen's website in the
Presentations section at
https://precigen.com/media/#id-presentations.
About Intrexon Corporation
Intrexon Corporation
(NASDAQ: XON) is Powering the Bioindustrial Revolution with Better
DNA™ to create biologically-based products that improve
the quality of life and the health of the planet through two
operating units – Intrexon Health and Intrexon
Bioengineering. Intrexon Health is focused on addressing
unmet medical needs through a diverse spectrum of therapeutic
modalities, including gene and cell therapies, microbial
bioproduction, and regenerative medicine. Intrexon
Bioengineering seeks to address global challenges across food,
agriculture, environmental, energy, and industrial fields by
advancing biologically engineered solutions to improve
sustainability and efficiency. Our integrated technology suite
provides industrial-scale design and development of complex
biological systems delivering unprecedented control, quality,
function, and performance of living cells. We call our synthetic
biology approach Better DNA®, and we invite you to
discover more at www.dna.com or follow us on Twitter at
@Intrexon, on Facebook, and LinkedIn.
About Precigen : Advancing Medicine with Precision™
Precigen is a dedicated discovery and
clinical stage biopharmaceutical company advancing the next
generation of gene and cellular therapies using precision
technology to target the most urgent and intractable diseases in
immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen also follows the science opportunistically in pursuit of
promising programs in emerging therapeutics. Our technologies
enable us to find innovative solutions for affordable
biotherapeutics in a controlled manner. Precigen operates as an
innovation engine progressing a preclinical and clinical pipeline
of well-differentiated unique therapies toward clinical
proof-of-concept and commercialization. Precigen was founded as a
wholly owned subsidiary of Intrexon Corporation (NASDAQ: XON)
and leverages a diverse portfolio of technology platforms to
advance human health. For more information about Precigen, visit
www.precigen.com or follow us on Twitter @Precigen and
LinkedIn.
Trademarks
Intrexon, Powering the Bioindustrial
Revolution with Better DNA, and Better DNA are trademarks of
Intrexon and/or its affiliates. Other names may be trademarks of
their respective owners.
Safe Harbor Statement
Some of the statements made in
this press release are forward-looking statements. These
forward-looking statements are based upon our current expectations
and projections about future events and generally relate to our
plans, objectives and expectations for the development of our
business. Although management believes that the plans and
objectives reflected in or suggested by these forward-looking
statements are reasonable, all forward-looking statements involve
risks and uncertainties and actual future results may be materially
different from the plans, objectives and expectations expressed in
this press release.
For more
information contact:
|
|
Intrexon Investor
Contact:
Steven
Harasym
Vice President,
Investor Relations
Tel: +1 (301)
556-9850
investors@dna.com
|
Intrexon Corporate
Contact:
Marie Rossi,
PhD
Vice President,
Communications
Tel: +1 (301)
556-9850
publicrelations@dna.com
|
Precigen Media
Contact:
Donelle M.
Gregory
press@precigen.com
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/intrexon-to-announce-third-quarter-financial-results-on-november-12th-300951014.html
SOURCE Intrexon Corporation; Precigen, Inc.